[HTML][HTML] Mesothelin: an immunotherapeutic target beyond solid tumors
JR Faust, D Hamill, EA Kolb, A Gopalakrishnapillai… - Cancers, 2022 - mdpi.com
Simple Summary This review summarizes the current knowledge on mesothelin's function,
its role in cancer, and opportunities for immunotherapeutic targeting of mesothelin …
its role in cancer, and opportunities for immunotherapeutic targeting of mesothelin …
Modular chemical construction of IgG-like mono-and bispecific synthetic antibodies (SynAbs)
In recent years there has been rising interest in the field of protein–protein conjugation,
especially related to bispecific antibodies (bsAbs) and their therapeutic applications. These …
especially related to bispecific antibodies (bsAbs) and their therapeutic applications. These …
[HTML][HTML] Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
M Wathikthinnakon, P Luangwattananun… - Scientific Reports, 2022 - nature.com
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …
A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin
A Chakraborty, M Onda, T O'Shea, J Wei, X Liu… - Molecular Cancer …, 2024 - AACR
Mesothelin (MSLN) is a cell-surface protein that is expressed on many cancers, which
makes it a popular target for antibody-based cancer therapy. However, MSLN is shed from …
makes it a popular target for antibody-based cancer therapy. However, MSLN is shed from …